SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

JNJ-632

Cat. No.:	HY-112564
CAS No.:	1572510-42-9
Molecular Formula:	$C_{18}H_{19}FN_2O_4S$
Molecular Weight:	378.42
Target:	HBV
Pathway:	Anti-infection

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (330.32 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6426 mL	13.2128 mL	26.4257 mL
	5 mM	0.5285 mL	2.6426 mL	5.2851 mL
	10 mM	0.2643 mL	1.3213 mL	2.6426 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.50 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (5.50 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.50 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).

IC_{50} & Target

HBV[1]

In Vitro

JNJ-632 is a capsid assembly modulator inhibiting hepatitis B virus (HBV). JNJ-632 inhibits HBV DNA HepG2.2.15 and HBV DNA HepG2.117 with EC_{50}s of 0.12 and 0.43 μM, respectively. In the high-content multiparameter cytotoxicity (HepG2), JNJ-632 shows EC_{20}s in the 10-30 μM range (considered weakly cytotoxic)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The single dose PK profile of JNJ-632 is evaluated in C57BL/6 mice following intravenous (iv) and oral (po) administration. JNJ-632 has a moderate plasma clearance of 34 mL/min/kg and a moderate volume of distribution of 1.3 L/kg. The oral bioavailability is 40% following oral administration of 10 mg/kg and 66% following oral administration of 50 mg/kg. JNJ-632 has moderate terminal elimination half-life with $t_{1/2}$s of 0.42±0.06 h, 1.1±0.67 h, 2.4±2.3 h, and 5.3±0.1 h for 2.5 mg/kg (iv), 10 mg/kg (po), 50 mg/kg (po), and 50 mg/kg (sc).To circumvent the first pass metabolism, JNJ-632 is also dosed subcutaneously at 50 mg/kg in C57BL/6 mice and this results in a concentration in plasma after 24 h of dosing of 102 ng/mL and concentration in liver after 24 h of dosing of 1297 ng/g[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration [1]

Mice[1]

The pharmacokinetic profile is evaluated in fed male C57BL/6 mice (n=3/group). Mice are i.v. injected with JNJ-632 at 2.5 mg/kg, formulated as a 0.5 mg/mL solution in PEG400/water (70/30), and blood samples are collected from the saphenous vein at 0.05, 0.17, 0.5, 1, 2, 4, 7, and 24 hours into EDTA-containing microcentrifuge tubes. JNJ-632 is administered p.o. at 10 and 50 mg/kg, formulated as 0.5 and 2.5 mg/mL suspension in methocel 0.5% w/v, and blood samples are collected from the saphenous vein at 0.5, 1, 2, 4, 7, 9 and 24 hours into EDTA-containing microcentrifuge tubes. JNJ-632 is administered s.c. at 50 mg/kg, and blood samples are collected. The blood samples are immediately centrifuged at 4°C and the plasma was stored at -20°C[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Sci Adv. 2023 Apr 14;9(15):eadg6265.
- Viruses. 2023 May 18, 15(5), 1195.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Vandyck K, et al. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA